Status:
COMPLETED
Chemoreflex Sensitivity in Chronic Kidney Disease
Lead Sponsor:
RWTH Aachen University
Collaborating Sponsors:
Heinrich-Heine University, Duesseldorf
SLK Kliniken Heilbronn GmbH
Conditions:
Chronic Kidney Disease
Cardiovascular Morbidity
Eligibility:
All Genders
18-90 years
Brief Summary
Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD) and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex sensitivity (CHR...
Detailed Description
Impaired hyperoxic chemoreflex sensitivity (CHRS) is assessed in patients with stage 3 CKD \[glomerular filtration rate (GFR) 30-59 ml/min/1.73 m2\], in patients with stage 4 CKD \[GFR 15-29 ml/min/1....
Eligibility Criteria
Inclusion
- Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29 ml/min/1.73 m²)
- For the reference Patients without evidence for CDK
Exclusion
- Patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00794872
Start Date
January 1 2007
End Date
November 1 2008
Last Update
November 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Division of Cardiology, Pulmonology and Vascular Medicine
Aachen, North Rhine-Westphalia, Germany, 52074